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BACKGROUND: The epigenome may be an important interface between environmental chemical exposures and human health. However, the links
between epigenetic modifications and health outcomes are often correlative and do not distinguish between cause and effect or common-cause rela-
tionships. The Adverse Outcome Pathway (AOP) framework has the potential to demonstrate, by way of an inference- and science-based analysis, the
causal relationship between chemical exposures, epigenome, and adverse health outcomes.
OBJECTIVE: The objective of this work is to discuss the epigenome as a modifier of exposure effects and risk, perspectives for integrating toxicoepige-
netic data into an AOP framework, tools for the exploration of epigenetic toxicity, and integration of AOP-guided epigenetic information into science
and risk-assessment processes.
DISCUSSION: Organizing epigenetic information into the topology of a qualitative AOP network may help describe how a system will respond to epi-
genetic modifications caused by environmental chemical exposures. However, understanding the biological plausibility, linking epigenetic effects to
short- and long-term health outcomes, and including epigenetic studies in the risk assessment process is met by substantive challenges. These
obstacles include understanding the complex range of epigenetic modifications and their combinatorial effects, the large number of environmental
chemicals to be tested, and the lack of data that quantitatively evaluate the epigenetic effects of environmental exposure.
CONCLUSION: We anticipate that epigenetic information organized into AOP frameworks can be consistently used to support biological plausibility
and to identify data gaps that will accelerate the pace at which epigenetic information is applied in chemical evaluation and risk-assessment para-
digms. https://doi.org/10.1289/EHP2322
Introduction
The epigenome is a factor that can be modified by environmental
chemical exposures. Epigenetic alterations (or the “epigenome”,
when considering epigenetics on a genome-wide scale) include
modifications to DNA, histone proteins that serve as a genome
scaffold, and other factors including noncoding RNAs that collec-
tively regulate the expression of genes without changing DNA
sequence. In short, modification to the epigenome can lead to a
change in phenotype without a change in genotype. Epigenetic
states are malleable and are influenced by both intrinsic (e.g.,
age, sex, genetic polymorphisms) and extrinsic (e.g., environ-
mental exposures, stress, diet) factors (Bowers and McCullough
2017). These “environmental factors” have quantitative effects
on the epigenome that influence health outcomes across life stages
and possibly across generations (Chamorro-García et al. 2013;
Manikkam et al. 2012; Skinner et al. 2013; Tracey et al. 2013). The
study of the epigenome causing adverse health effects of environ-
mental exposures, or “toxicoepigenetics,” is a rapidly expanding
field that has made marked progress in the past decade (Hansen
et al. 2011; Roadmap Epigenomics Consortium et al. 2015). Yet,
the possible biological pathways linking environmental exposures,
their impacts on the epigenome, and the health effects from expo-
sure are not entirely clear.
To help simplify the roles that epigenetics may play in media-
ting biological effects after exposure, epigenetic modifications
can be reduced into three effect groups. The first, an “adverse
effect,” can be defined as an exposure-induced epigenetic change
that results in either an adverse outcome or a new epigenetic
threshold vulnerable to a subsequent exposure. The second, an
“adaptive effect,” can be defined as an exposure-induced change
that primes the epigenome into a state protected from a subse-
quent exposure. The third, a “null effect,” can be defined as an
exposure-induced epigenetic change with no adverse or adaptive
outcome. Although null effects may pose no or low immediate risk
to the affected individual, it is possible that null effects may emerge
during sensitive life stages and/or propagate across generations.
Further, with respect to all three effect types, the contribution of an
exposure-induced epigenetic change to an adverse outcome can
vary depending on the biological context (e.g., developmental win-
dows of susceptibility and modulating factors such as disease).
Nevertheless, the fundamental challenge to including epigenetic
information in a risk assessment is identifying measurable
causal relationships between epigenetic modifications and health
outcomes.
A step toward discovering these causal relationships could
include collecting and organizing existing scientific evidence into
a framework that establishes evidence-based biological plausibil-
ity. The Adverse Outcome Pathway (AOP) paradigm (Ankley
et al. 2010) may provide the framework needed to do this, that is,
i.e., to link epigenetic study evidence (that may not inform mech-
anisms) with apical toxicological outcomes. AOPs are meant
to describe how perturbation of a biological system leads to a
particular adverse health outcome using components called mo-
lecular initiating events (MIEs), Key Events (KEs), Key Event
Relationships (KERs), and Adverse Outcomes (AOs) that are
supported by both biological plausibility and scientific evi-
dence (Table 1) (Villeneuve et al. 2014a). Progression along
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the AOP may occur as compensatory mechanisms or feedback
loops are overcome. AOPs originated from ecotoxicology as
a means to extend toxicity pathways and modes of action into
more holistic, yet systematic, descriptions of systems biology and
ecology interactions that inform pathology (Ankley et al. 2010;
Vinken et al. 2017). AOP development has been described previ-
ously (Villeneuve et al. 2014a, b), and specific guidance on devel-
oping AOPs is available (OECD 2013). AOPs are generally
accepted by regulatory agencies, and they are being extended as a
systematic framework for incorporating new and alternative meth-
ods into toxicity testing and risk assessment (OECD 2013, 2016;
Tollefsen et al. 2014). Conceptually, individual AOPs are a net-
work of components consisting of overlapping modules that can be
experimentally measured (i.e., end points or biomarkers) and used
to draw inferences about how a system will respond to a perturba-
tion. AOP components are often depicted as linear paths, but in
reality, the components are networked objects within a dimensional
biological space. This concept is critical when considering that
AOPs can be thought of as layered pages describing different path-
ways (e.g., DNA methylation, histone modification, gene expres-
sion) that collectively tell a story (supported by scientific evidence)
relating exposure, complex biology, and outcome. A more detailed
description of AOP networks and their applications can be found
in two related papers (Knapen et al. 2018; Villeneuve et al. 2018).
Collective AOP knowledge is integrated and disseminated to make
it tractable for domestic and international stakeholders to map
measured end-point or biomarker evidence to identify AOP net-
works and infer policy-relevant outcomes (see http://aopkb.org).
AOPs, however, lack dosimetry and are qualitative; therefore, they
must be transformed into a quantitative framework for practical
application toward risk assessment.
Nonetheless, the AOP paradigm may yield a clear, transpar-
ent, scientific, and evidence-based approach to causally linking
epigenome toxicity to otherwise correlative human health effects.
This approach is generally applicable to exposure-related disease
but requires expert curation. Therefore, this work extends the
field of toxicoepigenetics by not only describing the biology of
epigenetic modifications but also organizing those epigenome
toxicity pathways into an AOP-like framework. Using this struc-
tured approach helps to clarify challenges to practical application
of this knowledge as well as to experimental detection methods
that might inform epigenetic mechanisms and other data gaps.
The goal is to integrate existing science using an approach that
provides evidence-based biological plausibility that is needed to
apply observational and experimental information into the U.S.
Environmental Protection Agency (EPA) risk assessment para-
digm (NRC 2009).
Epigenetic Modifications
Epigenetic effects are often evaluated by examining modification
of DNA, histones, noncoding RNA, and changes in chromatin
structure. These modifications shape the genomic information
that is used to control DNA accessibility and to regulate cell- and
tissue-specific transcription, replication, and DNA repair. The hy-
pothesis is that exposure to environmental factors leads to epige-
netic (local) or epigenomic (global) effects that alter regulation
or expression (or both) of exposure-responsive genes. Changing
spatial and temporal patterns of gene regulation can affect organis-
mal development and physiologic (e.g., metabolic, endocrine, car-
diovascular, neurological, respiratory) function. However, although
some may be causative of disease, many are merely transient and
may have no phenotypic impact on health. Therefore, before organ-
izing epigenetic information into a biologically plausible frame-
work, it is important to understand what these modifications are
and their impacts on biology.
DNA methylation. To date, DNA methylation (5-methylcyto-
sine; “5-mC”) is the most-studied epigenetic modification associ-
ated with exposure. Genomic regions enriched in 5-mC are
typically transcriptionally repressed, compacted regions of the ge-
nome known as heterochromatin. Conversely, genomic regions
where 5-mC is sparse or absent are typically associated with genes
that are either active or poised to be induced. DNA methylation is
dynamic and is mediated by DNA methyltransferases (DNMTs)
and DNA demethylases (Ludwig et al. 2016). In mammals,
DNMT3a and DNMT3b establish patterns of DNA methylation
de novo during early embryo and germ cell development, and
DNMT1 maintains DNA methylation during replication. DNA
demethylation is mediated by passive dilution during DNA replica-
tion or by the Ten-eleven translocation (TET) family of DNA
demethylases, which actively oxidize 5-mC to 5-hydroxymethylcy-
tosine, 5-formylcytosine, and 5-carboxylcytosine (Bochtler et al.
2017).
These mechanisms are by no means all-inclusive, but they are
important when considering studies examining how extrinsic
factors such as diet, early-life exposures, socioeconomic status
(SES), and aging have affected DNA methylation patterns. For
example, S-adenosyl methionine (SAM) is a methyl group source
used during DNA methylation and is also consumed during the
detoxification of inorganic arsenic (iAs) to mono- and dimethy-
lated metabolites (MMA and DMA, respectively) (Bailey et al.
2013). In a cohort from Zamapan, Mexico, exposed to iAs [aver-
age 110 parts per billion ðppbÞ] in drinking water, (Bailey et al.
2013) reported a positive association between urinary MMA and
DMA levels and peripheral blood leukocyte DNA hypomethyla-
tion in the promoters of type 1 and type 2 diabetes mellitus target
genes. The same study participants were also evaluated for gly-
cated hemoglobin (Hba1c), and 15 out of the 16 subjects had
levels (>6%) indicative of prediabetes or diabetes status. The evi-
dence can be mapped to an AOP-like framework with the caveat
that AOPs are intended to be chemically agnostic. For example,
people were exposed to arsenic in drinking water (Figure 1, left-
most box), leading to an unknown molecular initiating effect. The
ingested arsenic was metabolized and eliminated as urinary
MMA and DMA that were positively associated with decreased
DNA methylation in people with diabetes (Figure 1, KE1 and
AO1). Although this example AOP is supported by limited and
correlative evidence, it is an example of how one may begin
organizing study data in a biologically plausible framework that
is clearly and transparently supported by accompanying evidence
tables (Tables 2 and 3).
Interestingly, the same cohort was used to identify a positive
association between hypermethylation (Figure 1, KE2) of a TP53
network and arsenic-induced skin lesions (Smeester et al. 2011).
This result was consistent with the findings of Chanda et al.
(2006), who also identified an association between arsenic-
Table 1. Description of adverse outcome pathway (AOP) components (OECD 2016; Villeneuve et al. 2014a).
Component Description
Molecular initiating event (MIE) The initial chemical–molecular interaction that is the starting point of an AOP.
Key event (KE) A measurable change in biological state that is essential for progression along an AOP.
Key event relationship (KER) A scientifically based connection that describes a directional relationship from one key event to another.
Adverse outcome (AO) An apical end point that is generally viewed as having regulatory significance.
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induced skin lesions and hypermethylation of the TP53 promoter
leading to decreased TP53 expression (KE3). TP53 is a tumor sup-
pressor, and its loss of activity propagates DNA damage (KE4), the
accumulation of mutations (KE4), and cancer (KE5) (Levine and
Oren 2009) (Figure 1A). It may be that arsenic limits methyl
donors, yet in mice prenatal folate supplementation worsened
health outcomes in male offspring exposed to iAs in utero (Tsang
et al. 2012). The lack of coherence between evidence streams is
clarified by evidence mapping and may provide a platform for
streamlining resources to address data gaps that might have other-
wise beenmissed.
Histone modifications and chromatin accessibility. DNA
strands are more than 2 in length, yet they are condensed into a
nucleus with a diameter of 5–10 lm by packaging DNA onto
nucleosomes that contain two molecules of the histone proteins
H2A, H2B, H3, and H4. Nucleosomal packaging of DNA
allows for high-order compaction but also creates the need for
controlled decompaction so that cellular functions such as tran-
scription, DNA replication, and DNA repair can occur. Histone
proteins have N- and C-terminal tails that extend outward from
the nucleosome core and are posttranslationally modified
(Kouzarides 2007). Histone tail modifications act as the letters
in an alphabet that direct the use of informa-tion encoded in the
genome; this is mediated by alterations to histone-DNA inter-
actions and the binding of specialized domains in chromatin-
interacting proteins (so-called “readers”) (Strahl and Allis
2000). These modifications are added or removed by classes of
enzymes (so-called “writers” and “erasers”) that are regulated by
cellular signaling networks and thus are responsive to the effects of
environmental exposures. Generally speaking, individual histone
modifications are described as “activating” (facilitating open chro-
matin structure and accessibility of DNA to RNA polymerase) or
“repressing” (facilitating a closed or condensed chromatin structure
that is not accessible to RNA polymerase); however, studies have
demonstrated a role for chromatin regions containing both activat-
ing and repressing modifications (“bivalent” domains) that regulate
gene expression (Bernstein et al. 2006). Chromatin states can also
vary depending on histone variants in nucleosomes. These variants
are targeted by variant-specific modifications and chromatin-
remodeling enzymes that regulate the density and distribution of
nucleosomes within gene regulatory regions (Clapier and Cairns
2009; Venkatesh and Workman 2015). The collective effects of
histone modifications, DNA methylation, histone variants, and
nucleosome remodeling at a given locus (or globally) leads to regu-
lation of both DNA accessibility and transcriptional initiation, elon-
gation, and termination.
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Figure 1. Putative Adverse Outcome Pathway (AOP) network for arsenic exposure. (A) Changes in DNA methylation leading to cancer and (B) changes in
histone modifications leading to psychiatric and neurological disorders. The gray oval and gray dashed lines indicate modifying factors or “risk” factors, all
dashed lines for weak weight of evidence or areas where there are data gaps. The up and down arrows within a key event (KE) box indicate the direction of
change of a KE. Note: AO, adverse outcome; KER, key event relationship.
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Histone acetylation. Histone acetylation plays a key role in
transcriptional regulation by modulating chromatin accessibility
as well as transcriptional activator recruitment to gene regulatory
regions. The acetylation of histone lysine residues is a reversible
modification that is added by histone acetyltransferases (HATs)
and removed by histone deacetylases (HDACs). Both HAT and
HDAC enzymes, such as GCN5/KAT2A and HDAC1, respec-
tively, are subunits in multiprotein complexes (Grant et al. 1997;
Lee and Workman 2007; Yang and Seto 2008) that target and
coordinate multiple histone reader, writer, and eraser functions.
The acetylation of lysine residues on histone tails aids chromatin
accessibility through two primary mechanisms. The first neutral-
izes positively charged lysine residues, leading to weakened
histone-DNA interactions (Li and Reinberg 2011). This effect is
most pronounced in H3 and H4, and the acetylation of a single
residue on H4 (H4K16) is sufficient to disrupt proper chromatin
folding (Kan et al. 2009). The second mechanism occurs when
acetylated lysine residues are bound by bromodomains, a motif
common in histone modifying and remodeling complexes.
Bromodomain binding is directed by acetyl lysine and is further
affected by other adjacent histone modifications (Filippakopoulos
and Knapp 2012).
Histone methylation. Histone tails are methylated and deme-
thylated by histone methyltransferases (HMTs) and histone deme-
thylases (HDMs), respectively, similar to histone acetylation.
However, unlike the single acetylation of individual lysine residues,
histone tails can be modified by mono- (me1), di- (me2), or trime-
thylation (me3) of the terminal amine group of lysine residues and
monomethylation, asymmetric dimethylation (dimethylation of one
of the two terminal amide groups), or symmetric dimethylation
(monomethylation of both the terminal amide groups) of arginine
residues (Kouzarides 2007). Further, whereas histone acetylation is
generally associated with open chromatin, histone methylation is
found in both open and condensed chromatin. The distribution of
specific methylated lysine residues is often associated with distinct
gene regulatory regions and function. Enhancers and active pro-
moters are typically enriched with H3K4me1 and H3K4me3,
respectively, whereas H3K36me2 and me3 are most abundant
within the bodies of actively transcribed genes (Guenther et al.
2007; Heintzman et al. 2007). In contrast, H3K9me3, H3K27me3,
and H4K20me3 are commonly associated with chromatin condensa-
tion (Kouzarides 2007). The location of these modifications is im-
portant for transcriptional regulation and is determined by the
recruitment and binding of a broad range of histone methyl-lysine
binding domains (Berger 2007; Martin and Zhang 2005). These
interactions are the foundation of downstream biological implica-
tions of histone methylation.
A broad range of toxic exposures, from arsenic to air pollution,
have been shown to alter histone acetylation and methylation pat-
terns through the dysregulation of either HAT/HDAC and HMT/
HDM expression or enzymatic activity. These effects can be simi-
larly applied to the AOP framework and are outlined in Figure 1B
and Table 3. Specifically using in vivo arsenic exposures as an
example, global H3K9me2 and H3K9ac (KE9) levels in peripheral
blood mononuclear cells were positively and negatively correlated
with arsenic and supported that arsenic exposure led to the repres-
sion of gene expression in a sex-specific manner (Chervona et al.
2012). These arsenic-mediated sex-specific epigenetic differences
were also observed during murine development in the dentate
gyrus (DG) and the frontal cortex (FC) (Tyler et al. 2015a).
Specifically, a 50 ppb developmental arsenic exposure increased
global H3K4me3 (KE10) levels, decreased histone demethylase
KDM5B, and increased the histone methyltransferase MLL
expression in the DG and FC of male mice only (KE8) (Figure
1B). The H3K4me3 enrichment mapped to the regulatory regions
of genes involved in cell development and growth, cell death and
survival, and neurological disorders (AO3) (Tyler et al. 2015b). In a
similar sex-specific manner, arsenic exposure increased H3K9ac
and the histone acetyltransferaseGCN5 in theDG,whereasH3K9ac
(KE7) and GCN5 (KE8) were decreased in the FC of male mice.
Evidence suggests that arsenic exposure during early development
is associated with psychiatric and cognitive dysfunction, yet the
Table 2. Evidence supporting adverse outcome pathway (AOP) network for DNA methylation (Figure 1A).
Key event Event description Key event relationship Reference
Exposure
IE Arsenic Exposure Sources of human exposure to inorganic arsenic (iAs) include drinking water,
diet, air, and soils (which can contain naturally occurring arsenic or
contamination from anthropogenic sources).
(ATSDR 2007)
Molecular
KE1 Decreased DNA
methylation
S-adenosyl methionine (SAM) is a methyl group source used during DNA
methylation and is also consumed during the detoxification of iAs to
mono- and dimethylated metabolites (MMA and DMA, respectively). The
consumption of SAM during As metabolism may limit the availability of
methyl donors.
(Bailey et al. 2013; Vahter and
Marafante 1988).
KE2 Increased DNA
methylation of TP53
promoter
In a cohort from Zamapan, Mexico, exposed to iAs (average 110 ppb) in
drinking water, a positive association between hypermethylation of a
TP53 network and arsenic-induced skin lesions was identified.
(Chanda et al. 2006; Smeester et al.
2011)
KE3 Decreased TP53 gene
expression
TP53 is a tumor suppressor and its loss of activity propagates DNA damage,
the accumulation of mutations, and cancer.
(Levine and Oren 2009)
Cellular/Tissue
KE4 Increased DNA damage Loss of TP53 activity propagates DNA damage. (Levine and Oren 2009)
KE5 Increased DNA mutation DNA damage may lead to the accumulation of mutations. (Levine and Oren 2009).
Organ
KE6 Increased tumors Alterations in the activity of tumor suppressor genes is positively correlated
with tumor progression.
(Yokota 2000)
Individual
AO1 Diabetes In a cohort from Zamapan, Mexico, exposed to iAs (average 110 ppb) in
drinking water, urinary MMA and DMA levels were positively associated
with peripheral blood leukocyte DNA hypomethylation in the promoters
of type 1 and type 2 diabetes mellitus target genes.
(Bailey et al. 2013).
AO2 Cancer Increased incidence of skin cancer was observed in populations drinking
water with high iAs concentration.
(Tseng et al. 1968; Tseng 1977)
Note: AO, adverse outcome; DMA, dimethylarsinic acid; IE, initiating event; KE, key event; MMA, monomethylarsonic acid.
Environmental Health Perspectives 045001-4
biological pathway linking epigenetic mechanism to outcome is
unclear.
Noncoding RNAs. Noncoding RNAs include microRNAs
(miRNAs), small nucleolar RNAs (snoRNAs), PIWI-interacting
RNAs (piRNAs) and long noncoding RNAs (>200 nucleotides,
e.g., large intergenic noncoding RNAs (lincRNAs), circular and
noncircular competitive endogenous RNAs (ceRNAs), and en-
hancer RNAs (eRNAs). Noncoding RNAs are derived from various
parts of the genome (exonic, intronic, intergenic, etc.) and are proc-
essed posttranscriptionally in different ways. Long noncoding RNA
can be processed into its mature form by RNase P, which cleaves
transfer RNA (tRNA)-like subunits from 30 termini of the mature
lncRNA and is then stabilized by formation of a 30 triple RNA
helix (Wilusz et al. 2012). miRNA biogenesis has been shown to
occur through Microprocessor complex processing of lncRNAs
(Dhir et al. 2015), but miRNAs are primarily generated from
intronic and exonic regions of protein-coding genes. Commonly, a
long primary miRNA (pri-miRNA) is cleaved by the Microproc-
essor complex, resulting in a precursor miRNA (pre-miRNA), and
exported from the nucleus by Exportin-5 and RanGTP (Slezak-
Prochazka et al. 2010). Pre-miRNA is then further processed into a
∼ 21 bp mature miRNA duplex by Dicer cleavage (Hutvágner et al.
2001). The sense or antisense strand is then loaded into the RNA-
induced silencing complex (RISC) and is then used to target mes-
senger RNA for degradation or to inhibit translation of the gene
product.
MicroRNAs are altered by environmental chemical expo-
sures, and these changes have been linked to disease and suscep-
tibility. A panel of miRNAs were associated with short-term
exposure of foundry workers to mixed particulate matter (PM)
components: miR-122 was associated with lead exposure, miR-
21 with 8-OH-dG, and miR-146 with lead and cadmium expo-
sures (Bollati et al. 2010). In another observational study,
miR-21 and miR-221 urine levels were positively associated with
arsenic and lead levels in school-age children with microalbumi-
nuria (Kong et al. 2012). Further, a panel of miRNAs found in
cord blood were correlated with in utero arsenic exposure—
including let-7a, miR-107, and miR-26b—that were also associ-
ated with cancer, diabetes, and immune response networks (Rager
et al. 2014). Related to the AOP example in Figure 1, in vitro ex-
perimental studies do provide mechanistic evidence in support of
both miR-200b– (Wang et al. 2011, 2014) and miR-190–
(Beezhold et al. 2011) mediated cancer pathogenesis in response
to arsenic dosing. Yet, collectively, the evidence streams lack
coherence for anchoring exposure to possible pathways leading to
adverse outcomes.
Despite the evidence that miRNA expression profiles were
altered by environmental exposure, evidence that these alterations
directly affected molecular progression to an adverse health out-
come was unclear. However, these measurements may be valuable
biomarkers of exposure. For example, miRNAs are detected in a
number of different biofluids (e.g., blood, urine, sputum) and are
stable in these matrices (Arroyo et al. 2011; Wang et al. 2010).
These biofluid miRNA measurements are particularly valuable
because they can indicate tissue-specific toxicity sooner and more
robustly than traditional clinical protein biomarkers (Harrill et al.
2016). Other noncoding RNAs might also be important rapid or
stable biomarkers of cellular response to exposures. For example,
eRNAs are a type of lncRNA that promote gene enhancer and
promoter interaction and transcriptional machinery recruitment
through chromatin remodeling (Li et al. 2016). After cellular per-
turbation, eRNA response is rapid (<10minutes), as with peroxi-
some proliferator activated receptor gamma (PPARc)-mediated
up-regulation with rosiglitazone exposure in mature adipocytes,
and is strongly associated with steady-state mRNA levels that
mediate cellular response (Step et al. 2014). Similarly, circular
competitive endogenous RNA (or circRNA) is a looped lncRNA
derived from various regions of the genome. circRNAs may regu-
late miRNA (and other transcripts) by acting as a molecular
“sponge” through multiple binding sites for specific miRNA,
thereby limiting miRNA seed regions to interact and subsequently
suppress messenger RNA targets (Hansen et al. 2013; Memczak
et al. 2013). circRNAs have been linked to diseases such as cancer
and, similar to miRNA, are stable, are present in circulating whole
blood, and have tissue-specific origins (Hou and Zhang 2017).
Notably, there is debate whether noncoding RNAs should be
considered an epigenetic mechanism because miRNA can be
regulated by epigenetic mechanisms, and the epigenetic machin-
ery itself can be regulated by miRNA expression (Saito et al.
2006; Tuddenham et al. 2006). For example, the miRNA (miR)-
29 family can target the de novo methyltransferases DNMT3A
and DNMT3B (Fabbri et al. 2007). In non-small cell lung cancer,
this targeting leads to an aberrant pattern of DNA methylation in
cancer cells. Further, DNA hypermethylation and increased ly-
sine methylation of histones H2K9 and H3K27 can affect the per-
sistent and decreased expression of miR-375 in mouse liver after
withdrawal of the nongenotoxic carcinogen furan (de Conti et al.
2016). However, the interdependency of miRNA and other
Table 3. Evidence supporting adverse outcome pathway (AOP) network for histone methylation (Figure 1B).
Key event Event description Key event relationship Reference
Exposure
IE Arsenic exposure Sources of human exposure to inorganic arsenic include drinking
water, diet, air, and soils (which can contain naturally occurring
arsenic or contamination from anthropogenic sources).
(ATSDR 2007)
Molecular
KE7 Decreased histone acetylase or
increased histone deacetylase activity
Arsenic exposure increased the histone acetyltransferase GCN5 in the
DG, whereas GCN5 was decreased in the FC.
(Chervona et al. 2012)
KE8 Increased histone methyltransferase or
decreased histone demethylase
activity
Developmental arsenic exposure (50 ppb decreased histone
demethylase KDM5B and increased expression of the histone
methyltransferase MLL in the DG and FC of male mice only.
(Tyler et al. 2015a, 2015b)
KE9 Decreased H3K9ac In vivo arsenic exposure was negatively correlated with global
H3K9ac levels in peripheral blood mononuclear cells in a
sex-specific manner. Histone acetyltransferase GCN5 was increased
in the DG, whereas H3K9ac and GCN5 were decreased in the FC.
(Chervona et al. 2012)
KE10 Increased H3K4me3 Developmental arsenic exposure (50 ppb) increased global H3K4me3
levels.
(Tyler et al. 2015a, 2015b)
Individual
AO3 Psychiatric and neurological disorders Arsenic exposure was positively correlated with developing psychiat-
ric disorders and cognitive dysfunction.
(Brinkel et al. 2009; Zierold et
al. 2004)
Note: AO, adverse outcome; DG, dentate gyrus; FC, frontal cortex; IE, initiating event; KE, key event.
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mechanisms that direct epigenetic phenotype is well documented
and, therefore, is considered in the context of epigenetic events
leading to adverse health outcomes.
Gap-Filling with Epigenetic and Epigenomic Methods
Early toxicoepigenetic studies have demonstrated that environmen-
tal exposures can alter the epigenome, yet the mechanistic linkage
between exposure and epigenetic modification is not clear (iAs
example, Figure 1). Chemicals could have a direct impact on the
activity of epigenetic modification enzymes (HDACS, DNMTs,
etc.), could block enzymes (such as DNMT) from accessing DNA
by activating transcription factors that bind DNA, or both. These
potential mechanisms are further complicated by the functional
consequence of biallelic epigenetic-directed gene regulation
(Cheung et al. 2017) and extrinsic factors, such as diet, that might
limit the availability of methyl donors (Tsang et al. 2012).
Furthermore, the premise that all epigenetic modifications lead to
changes in gene expression questions the practical limitations and
scope of some epigenetic assays that are expensive and do not
readily allow for evaluation of environmental effects on multiple
epigenetic modifications from a single sample. However, changes
in gene expression may not always correlate with epigenetic modi-
fication. Further, measurement methods cannot be equally
weighted owing to variation in assay sensitivity, specificity, accu-
racy, and precision. Therefore, recent advances in epigenetic
assays, mainly focusing on various scalable assays that not only
target DNA methylation and histone modifications but also pheno-
type, are presented with the understanding that the relevance of
each approach to specific science questions may depend upon
study quality aspects and prospective design.
Molecular approaches. DNA methylation. DNA methyla-
tion, that is, 5-mC, can be measured by a variety of whole genome
and site-specific approaches. Whereas traditional quantitative
methods measure cytosine methylation using high-performance
liquid chromatography (HPLC) or mass spectrometry, a more
common practice uses a bisulfite conversion step before analysis
by sequencing. During bisulfite conversion, DNA is treated with
sodium bisulfite, which chemically converts unmethylated cyto-
sines to uracil, a base read during DNA sequencing as thymine. By
Table 4. Epigenetic modification detection methods.
Modification Detection method Description Pros/cons
DNA methylation Methylation array Bisulfite-treated DNA is hybridized to a DNA
microarray, and the ratio of methylated to
unmethylated CpGs is assessed. Includes
Illumina-based bead arrays.
Genome-scale, site-specific measure-
ments. Low to medium throughput.
Low to medium cost.
Methylated DNA
immunoprecipitation (MeDIP)
DNA is fragmented, and methylated regions are
immunoprecipitated with 5-mC capture beads.
Captured DNA is eluted and sequenced.
Genome-scale, site-specific measure-
ments biased towards hypermethylated
regions. Low throughput. Medium to
high cost.
Whole genome bisulfite sequenc-
ing (WGBS)
Bisulfite-treated DNA is sequenced without any
enrichment, thereby measuring the entire
genome.
Genome-wide measurements of DNA
methylation. Low throughput. High
cost.
Reduced representation bisulfite
sequencing (RRBS)
Similar to WGBS, but DNA is restriction-
enzyme digested to enrich for CpG-rich DNA.
DNA is then bisulfite-treated and sequenced.
Genome-scale, biased for CpG-rich
DNA. Low throughput. Medium cost.
Nucleosome positioning
and histone
modifications
Chromatin immunoprecipitation
with sequencing (ChIP-seq)
Antibodies specific to histone modifications (i.e.,
those associated with active or repressed
chromatin) are used to immunoprecipitate
crosslinked DNA, which is then subject to
next-generation sequencing.
Genome-wide measurement of histone
location and modification type. Low
throughput. Medium cost.
Drop-ChIP Micrococcal nuclease (MNase), detergents, DNA
barcodes, and sample DNA are combined using
a microfluidic method to form nucleosomal
regions flanked by DNA barcodes. The
chromatin is immunoprecipitated, amplified,
and sequenced.
Genome-scale measurements with sin-
gle-cell profiling of chromatin state.
Low throughput. Medium to high cost.
Assay for Transposase-Accessible
Chromatin with high-throughput
sequencing (ATAC-seq)
Hyperactive Tn5 transposase is integrated into
accessible regions of the genome. Adaptors tag
the locus and serve as templates for PCR
amplification of sequences.
Genome-scale measurements with high
reproducibility and resolution. Low
throughput. Medium to high cost.
Chromatin desilencing CMV-driven GFP reporter A plasmid encoding GFP is stably transfected
and selected for absence of GFP expression.
The CMV-driven promoter is highly active, and
its silencing suggests integration into a
repressive chromatin environment. Subsequent
desilencing results in GFP expression.
Phenotypic measurement not specific for
a genomic region. High-throughput
assessment of chromatin desilencing
not applicable to transgenerational
effects. Low cost.
Transgenic let-858::GFP
Caenorhabditis elegans
The transgene let-858::GFP encodes a nuclear-
localized GFP fusion protein and is expressed
in all somatic nuclei. Under normal conditions
at baseline, GFP is epigenetically silenced. C.
elegans DNA is unmethylated. GFP expression
would suggest chromatin desilencing by histone
modification independent of DNA methylation.
In vivo. Phenotypic measurement not
specific for a genomic region. High-
throughput assessment independent of
DNA methylation. Low cost.
Developmental and life-
stage effects
Daphnia Alternative invertebrate model that offers several
phenotypic end points affected by epigenetic
regulation. A useful tool for Tier 2 or follow-up
screening evaluating the effects of dose and
duration.
Invertebrate, developmental, and life-
stage model with long culture time.
Low to high throughput. Low cost.
Note: CMV, cytomegalovirus; GFP, green fluorescent protein; PCR, polymerase chain reaction.
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contrast, methylated cytosines are protected and will be read as
cytosines. The bisulfite conversion and sequencing method is often
considered the gold standard in validating methylation results from
other assays such as MeDIP (see Table 4). The type of approach to
be used depends on the cellular context and the purpose, that is, to
examine global or site-specific methylation profiles. Of the DNA
methylation approaches included, reduced representation bisulfite
sequencing (RRBS) often offers a good compromise in terms of
coverage and cost: It enriches for CpG islands and repetitive ele-
ments, but coverage is lower than in the other methods. Of note,
RRBS and other methylation-detection methods have limitations
in terms of coverage, sensitivity, cost, and sample size that might
be solved by bisulfite sequencing combined with bead arrays
(Bibikova et al. 2006), an adaptation of Illumina’s high-throughput
GoldenGate® single nucleotide polymorphism (SNP) sequencing
technology, which allows multiplexed detection of the methylation
status of 1,536 CpG sites for 371 genes in each well of a 96-well
plate using 250 ng of genomic DNA. Finally, 5-hydroxymethyl cy-
tosine (5-hmC), a 5-mC degradation intermediate that has some
potential functions of its own (Hackett et al. 2013; Kafer et al.
2016), is an increasingly important object of study, and techniques
to identify its presence by adapting bisulfite conversion methods
have been developed (Field et al. 2015).
Chromatin accessibility and histone modifications. Several
different methods currently exist to assess other chromatin fea-
tures in addition to DNA methylation. These methods can be di-
vided into two broad categories: those that assess nucleosome
positioning as a proxy for active/inactive chromatin and those
that more specifically examine various types of histone modifica-
tions commonly associated with either transcriptional activity or
repression (such as H3K4me3 or H3K9me3, respectively) (Bock
and Lengauer 2008; Tsompana and Buck 2014) (Table 4). In
most cases, the large amount of chromatin needed to accurately
assess chromatin composition has precluded the development of
high-throughput methods. However, the Drop-ChIP (Rotem et al.
2015) and Assay for Transposase-Accessible Chromatin with
high-throughput sequencing (ATAC-Seq) approaches may cir-
cumvent this problem by profiling at the single-cell or well level
(Table 4) (Bao et al. 2015; Buenrostro et al. 2015). Drop-ChIP is
an adaptation of the chromatin immunoprecipitation and sequenc-
ing (ChIP-seq) method and combines the use of microfluidic
devices with nucleosome tagging and chromatin immunoprecipi-
tation steps (Rotem et al. 2015). The tags allow single-cell profil-
ing of their chromatin but also, via the aggregation of data from
multiple cells of the same type, reconstruction of a high-
resolution profile (Rotem et al. 2015). Drop-ChIP has not yet
been adapted as a high-throughput platform, but it is tentatively
possible to produce droplets of different cell types in a sequential
manner that would be fused with different sets of bar codes,
thereby creating a multiplexed assay. In contrast, ATAC-Seq
shows a high degree of reproducibility and resolution for map-
ping accessible (i.e., open, chromatin-rich) regions, and requires
little sample input. Thus, this method probes for genomic regions
of lower nucleosome density and has been adapted for cells in
culture in a 96-well format (Bao et al. 2015). Drop-ChIP and
ATAC-Seq represent two practical and advantageous methods
that require low material input and provide high-resolution chro-
matin profiling and mapping. These methods may be very useful
for assessing epigenetic changes in response to multiple chemi-
cals or in dose–response applications.
Phenotypic approaches. In contrast to the direct-measure mo-
lecular approaches, phenotypic approaches have the advantage of
directly screening chemicals for epigenetic effects. These meth-
ods could be used for chemical screening followed by measuring
epigenetic marks through the assays described above. Several
approaches are presented, in cell culture and in vivo, that may be
leveraged for a chemical’s epigenetic impact.
Cell culture setting. Martinez and colleagues describe the
use of cytomegalovirus (CMV)-driven green fluorescent protein
(GFP) reporter in mouse or human cell lines for chemical screen-
ing (Johnson et al. 2008; Martinez et al. 2006). In their assay
scheme, a plasmid encoding GFP and the neo gene is transfected
and is then selected for integration over several passages using
G418 selection. Stable lines are then selected for both G18 resist-
ance and absence of GFP expression, surmising that silencing of
the highly transcriptionally active CMV promoter would repre-
sent an integration in a repressive chromatin environment. This
approach was first validated using HDAC inhibitors and was then
applied to small molecule screening (Johnson et al. 2008). By
performing a screen against 69,137 small molecules, the authors
were able to identify novel chemicals that acted as chromatin
desilencers and to extract structure–activity relationships. This
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tantalizing approach is similar to the nematode assay described
below and has the advantage of high scalability, but it does not
allow the monitoring of epigenetic effects across generations.
Caenorhabditis elegans. The nematode Caenorhabditis ele-
gans is a free-living roundworm that has been extensively used
as a model system for the study of a wide variety of cellular and
developmental processes. Of particular relevance is that C. ele-
gans lacks 5-mC, and it has been used for the identification of
novel chromatin-regulating factors as well as for toxicity studies
(Ferreira and Allard 2015; Lundby et al. 2016; Parodi et al.
2015). A transgenic let-858::GFP roundworm has recently been
adapted in a fluorescence-based assay that evaluates chemical
effects on removal of chromatin marks such as H3K4 methylation
and the addition of repressive marks such as H3K9 methylation
independent of DNA methylation in the germline (Table 4)
(Kelly et al. 1997). The strain can therefore be used as a sensor to
detect chemical exposures that lead to chromatin deregulation
and desilencing. Worms are amenable to culture in 96-well plates
and can be imaged in 96- or 384-well plates; therefore, the
method is potentially scalable. Initial validation of the assay for
chemical screening has been reported using known chemical
inhibitors of chromatin-modifying enzymes such as valproic
acid, a well-characterized histone deacetylase inhibitor (Lundby
et al. 2016).
Daphnia. The microcrustacean Daphnia collectively refers to
a collection of species, most commonly D. magna and D. pulex,
that have been used for ecological, environmental, and genetic
studies (Harris et al. 2012). Daphnia offers several key advantages
for epigenetic studies compared with other, perhaps more com-
mon, model organisms such as C. elegans and Drosophila mela-
nogaster. First, Daphnia research over the last 150 y has generated
a wealth of ecological data that encompass a deep understanding
of its response to a variety of ecotoxicological conditions (Harris
et al. 2012; Stollewerk 2010). Second, Daphnia shows a repertoire
of epigenetic modifications that also include DNA methylation, a
mark that has been shown to be responsive to environmental expo-
sures (Robichaud et al. 2012; Vandegehuchte et al. 2009). Third,
Daphnia species offer a wide variety of characteristics and pheno-
types, such as egg type, growth, fertility and body morphs, that are
highly dependent on environmental cues and on epigenetic marks.
Variants in body morphs, such as Daphnia exhibiting a helmet or a
neck tooth formation, are induced in response to the presence of
predators, whereas variants in body length (e.g., growth) and repro-
duction (e.g., number of progeny) have been shown to be sensitive
to chemical inhibitors ofDNAmethylation such as 5-azacytidine (5-
aza) and the pesticide vinclozolin (Vandegehuchte et al. 2010). For
example, 5-aza reduces both length and reproduction in the parental
generation (F0) of D. magna as well as in their progeny (F1;
Vandegehuchte et al. 2010). However, vinclozolin only affects
growth in the F0 and does not affect reproduction (Harris et al. 2012;
Vandegehuchte et al. 2010). With their small size, 1–5 mm,
Daphnia species are amenable to in vitro culture conditions and
assays. However, the chemical characterization of their epigenetic
regulation requires culture over several days (up to 7 d). Although
slow, this alternative model is a valuable tool for the validation of
epigenetic effects initially observed in othermodel systems.
The assays described above all have the potential to illuminate
the study of environmental influences on the epigenome. The
choice of strategy is highly dependent on the context of the study.
For example, use of the C. elegans model may not offer the best
context to study the epigenomic perturbation in a cell type that can
be simply obtained from human or mouse. However, the high
degree of conservation of epigenetic pathways and the ability to
easily follow epigenetic modifications over several generations
make this model highly suitable for transgenerational studies. The
choice of platform is also dependent on the amount of material and
the degree of data complexity required. For example, ATAC-seq
requires little starting material and can provide a high-resolution
map of genomic loci of higher chromatin accessibility. However,
this method will not provide direct mechanistic insight into local
epigenetic alterations such as changes in methylation or histone
mark patterns. In those instances, RRBS or Drop-ChIP might be
better options even if slightly more material is needed. Finally,
cross-platform validation is likely to increase the reliability of the
outcome. For example, one could start screening chemicals for a
phenotypic readout, such as the use of the cell culture model
described above, and follow the positive hits with ATAC-seq to
assess chromatin relaxation across the genome.
Methodological Challenges. To determine whether epige-
netic changes associated with exposure might contribute to
adverse health outcomes, a baseline epigenetic state is needed for
comparison. Several large research consortia have focused on
generating reference epigenomic maps from normal human cell
and tissue types, including the National Institutes of Health
(NIH) Roadmap Epigenomics Program (http://www.roadmape
pigenomics.org/) (Roadmap Epigenomics Consortium et al.
2015) and the International Human Epigenome Consortium (http://
ihec-epigenomes.org) (Stunnenberg et al. 2016). Reference maps
such as these can be useful guides for interpreting exposure-
associated epigenetic differences. These reference maps help to
distinguish changes that may be directly linked to the exposure
from changes that are more reflective of the relative ratios of spe-
cific cell types that make up a heterogeneous tissue sample. In
essence, sample source and cell type heterogeneity (i.e., human
genetic heterogeneity) are problematic in epigenomic studies
because human samples often consist of blood (owing to ease of
access) that is composed of mixed cell types. Each cell type has a
unique epigenetic profile, and the relative proportion of each cell
type in a sample may vary as a result of exposure (Stiegel et al.
2016). Reference resources and maps for a given cell type are typi-
cally collected from a limited number of people and provide no in-
formation about baseline epigenetic variation at a given locus. The
implication is that high levels of underlying epigenetic variation
could make it difficult to distinguish exposure-induced “signal”
from background noise.
Discussion
Interpreting the Evidence
There is a clear challenge to linking epigenetic effects with out-
comes in chemical risk assessment that supports the use of the
AOP framework to organize epigenetic data into an inference-
based biologically plausible framework. Integration of the evidence
into conceptual frameworks, such as those depicted in Figure 1 and
supported by Tables 2 and 3, improves interpretation of scientific
information that, if not properly contextualized, is otherwise per-
ceived as tenuous. For example, arsenic (and likely many other
environmental toxicants) is not directly mutagenic, but it invokes
epigenetic changes that may dysregulate the expression of tumor
suppressors or oncogenes (Shinjo and Kondo 2015). Furthermore,
epigenome reprogramming occurs during early embryonic and pri-
mordial germ cell development (Hackett and Surani 2013) and
may restore epigenetic marks altered by prior exposure. However,
exposures that occur during these developmentally sensitive win-
dows may also lead to permanent reprogramming of the methyl-
ome, thus playing a role in the developmental origins of health and
disease (Desai et al. 2013; Newbold et al. 2007), possibly including
malignancy.
AOP evidence mapping exercises are broadly applicable to
other environmental toxicants (e.g., metals, trichloroethylene and
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its metabolites, air pollution, benzene) that have been character-
ized as inducing epigenetic toxicity and have been reviewed
(Bowers and McCullough 2017; Hodjat et al. 2017). The implica-
tion is that real-world exposures uniquely alter pharmacodynam-
ics or molecular initiating effects that propagate across biology to
achieve homeostasis, similar to a ripple in a pond, and converge
at key events. These key events can be explicitly measured, used
to infer outcome, and interpreted in the context of additional risk
and modulating factors, such as genetic susceptibility, disease
status, or nutrition. These concepts are critical for evaluating epi-
genetic modifications where the adversity depends on adaptive,
adverse, or null effect types.
There is light at the end of the tunnel for epigenetic research-
ers hoping to intersect with the risk assessment community.
Evidence-based mapping (ideally guided by a systematic litera-
ture search) can be used to help formulate the questions and to
direct future research and resources (James et al. 2016) to areas
where further scientific understanding of epigenetics is needed.
Figure 2 outlines a general approach for evaluating an environ-
mental protection goal where the state of the science is systemati-
cally analyzed using structured methods to identify existing
studies that address the relevant questions (e.g., are epigenetic
modifications adverse?). The relevant body of literature is sys-
tematically evaluated, considering the design, methods, conduct,
and documentation irrespective of the study results. Assessing
the study quality is an essential step to rule out bias before
extracting results for interpretation (Ågerstrand et al. 2011;
Beronius et al. 2014a, 2014b; Sterne et al. 2016). Even so, evalu-
ating the significance of observational and experimental response
data without proper biological context could result in meaning-
less and confusing interpretation. Organizing the evidence into a
biologically based AOP framework can provide a roadmap from
effect to outcome, help shape future research questions, and fill
(or highlight) evidence gaps.
Confidence in epigenetic data supported by an AOP frame-
work may be enhanced by including weight of evidence and visu-
als. Weight of evidence guidance for the AOP framework has
been previously described in the Organisation for Economic Co-
operation and Development (OECD) (2016) Users’ Handbook
supplement to the Guidance Document on the Reporting of
Defined Approaches to be Used within Integrated Approaches to
Testing and Assessment that identifies biological plausibility, em-
pirical support, and uncertainties or inconsistencies that one key
event will lead to another that can be cited from the literature.
These evidence streams could be depicted by solid versus dashed
arrows (Figure 1), the weight of an arrow or outline of a box, or
some other type of quantitative visualization. A table with referen-
ces, doses, study details, study types (epidemiologic, experimental,
or controlled human exposure) could also complement the AOP.
Ultimately, however, these qualitative AOP frameworks are more
useful for hazard identification and would require translation into a
framework that captures a quantitative understanding between ex-
posure dose and effect. Nonetheless, organizing evidence using the
AOP framework is an approach to clearly evaluating the biological
evidence and should boost confidence during interpretation and in-
formation dissemination.
Conclusion
Toxicoepigenetics is a dynamic field that may have broad impli-
cations in human health and disease; however, there are chal-
lenges to be overcome before epigenetic data can be readily
integrated into the chemical evaluation process. Organizing epi-
genetic information into AOP frameworks may help identify
cause-and-effect relationships that help guide a science-based
analysis of how a system will respond to epigenetic perturbations.
The concept of harmonizing toxicological information using a
broad toxicological framework to improve decision making is not
new and was recently reviewed (Edwards et al. 2016). This
approach could address the “basic problem in risk assessment . . .
the incompleteness of data” (NRC 2009, p. 22). It is possible that
epigenetic data can be layered with other diverse data streams and
be used to inform events within the AOP framework so that there is
sufficient evidence to conclude clear relationships between expo-
sure, epigenetic modification, and adverse outcome. Yet, the suc-
cess of the AOP framework and the pace at which epigenetic
information is incorporated into the risk-assessment process
depend on expert-driven AOP development and broad participa-
tion from the toxicoepigenetic community. The AOP paradigm
may provide a platform for integrating toxicoepigenetic informa-
tion with other biological pathways so that we may better under-
stand if exposure-mediated epigenetic effects have an impact on
adverse outcomes. This work breaks down barriers to incorporat-
ing epigenetic studies in science-based chemical risk assessment
by describing a practical and integrative science-based approach.
Acknowledgment
The authors would like to thank D. Diaz Sanchez, J. Rogers, S.
Dutton, L. D-Amico, and J. Vandenberg for their technical
review and A. Jarabek for scientific advice.
Funding for this study came from the U.S. Environmental
Protection Agency Office of Research and Development. The
research described in this article has been reviewed by the National
Center for Environmental Assessment of U.S. Environmental
Protection Agency and approved for publication. The views
expressed in this paper are those of the authors and do not
necessarily reflect the views or policies of the U.S. Environmental
Protection Agency. Mention of trade names or commercial
products does not constitute endorsement or recommendation for
use.
References
Ågerstrand M, Küster A, Bachmann J, Breitholtz M, Ebert I, Rechenberg B, et al. 2011.
Reporting and evaluation criteria as means towards a transparent use of ecotox-
icity data for environmental risk assessment of pharmaceuticals. Environ Pollut
159(10):2487–2492, PMID: 21763042, https://doi.org/10.1016/j.envpol.2011.06.023.
Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al.
2010. Adverse outcome pathways: a conceptual framework to support ecotoxi-
cology research and risk assessment. Environ Toxicol Chem 29(3):730–741,
PMID: 20821501, https://doi.org/10.1002/etc.34.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. 2011.
Argonaute2 complexes carry a population of circulating microRNAs independ-
ent of vesicles in human plasma. Proc Natl Acad Sci U S A 108(12):5003–5008,
PMID: 21383194, https://doi.org/10.1073/pnas.1019055108.
ATSDR (Agency for Toxic Substances and Disease Registry). 2007. Toxicological
Profile for Arsenic. Atlanta, GA:ATSDR. https://www.atsdr.cdc.gov/toxprofiles/
tp2.pdf [accessed 16 November 2017].
Bailey KA, Wu MC, Ward WO, Smeester L, Rager JE, García-Vargas G, et al. 2013.
Arsenic and the epigenome: interindividual differences in arsenic metabolism
related to distinct patterns of DNA methylation. J Biochem Mol Toxicol
27(2):106–115, PMID: 23315758, https://doi.org/10.1002/jbt.21462.
Bao X, Rubin AJ, Qu K, Zhang J, Giresi PG, Chang HY, et al. 2015. A novel ATAC-
seq approach reveals lineage-specific reinforcement of the open chromatin
landscape via cooperation between BAF and p63. Genome Biol 16:284, PMID:
26683334, https://doi.org/10.1186/s13059-015-0840-9.
Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X, et al. 2011. miR-190-
mediated downregulation of PHLPP contributes to arsenic-induced Akt activa-
tion and carcinogenesis. Toxicol Sci 123(2):411–420, PMID: 21750348,
https://doi.org/10.1093/toxsci/kfr188.
Berger SL. 2007. The complex language of chromatin regulation during transcription.
Nature 447(7143):407–412, PMID: 17522673, https://doi.org/10.1038/nature05915.
Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. 2006. A biva-
lent chromatin structure marks key developmental genes in embryonic stem
cells. Cell 125(2):315–326, PMID: 16630819, https://doi.org/10.1016/j.cell.2006.02.
041.
Environmental Health Perspectives 045001-9
Beronius A, Hanberg A, Zilliacus J, Rudén C. 2014a. Bridging the gap between aca-
demic research and regulatory health risk assessment of endocrine disrupting
chemicals. Curr Opin Pharmacol 19:99–104, PMID: 25238457, https://doi.org/10.
1016/j.coph.2014.08.005.
Beronius A, Molander L, Rudén C, Hanberg A. 2014b. Facilitating the use of non-
standard in vivo studies in health risk assessment of chemicals: a proposal to
improve evaluation criteria and reporting. J Appl Toxicol 34(6):607–617, PMID:
24481642, https://doi.org/10.1002/jat.2991.
Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. 2006. High-throughput
DNA methylation profiling using universal bead arrays. Genome Res 16(3):383–
393, PMID: 16449502, https://doi.org/10.1101/gr.4410706.
Bochtler M, Kolano A, Xu GL. 2017. DNA demethylation pathways: additional play-
ers and regulators. Bioessays 39(1):1–13, PMID: 27859411, https://doi.org/10.
1002/bies.201600178.
Bock C, Lengauer T. 2008. Computational epigenetics. Bioinformatics 24(1):1–10,
PMID: 18024971, https://doi.org/10.1093/bioinformatics/btm546.
Bollati V, Marinelli B, Apostoli P, Bonzini M, Nordio F, Hoxha M, et al. 2010. Exposure
to metal-rich particulate matter modifies the expression of candidate microRNAs
in peripheral blood leukocytes. Environ Health Perspect 118(6):763–768, PMID:
20061215, https://doi.org/10.1289/ehp.0901300.
Bowers EC, McCullough SD. 2017. Linking the epigenome with exposure effects
and susceptibility: the epigenetic seed and soil model. Toxicol Sci 155(2):302–
314, PMID: 28049737, https://doi.org/10.1093/toxsci/kfw215.
Brinkel J, Khan MH, Kraemer A. 2009. A systematic review of arsenic exposure
and its social and mental health effects with special reference to Bangladesh.
Int J Environ Res Public Health 6(5):1609–1619, PMID: 19543409, https://doi.org/
10.3390/ijerph6051609.
Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. 2015. ATAC-seq: a method for
assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol
109(1): 21.29.1–21.29.9, PMID: 25559105, https://doi.org/10.1002/0471142727.
mb2129s109.
Chamorro-García R, Sahu M, Abbey RJ, Laude J, Pham N, Blumberg B. 2013.
Transgenerational inheritance of increased fat depot size, stem cell reprog-
ramming, and hepatic steatosis elicited by prenatal exposure to the obesogen
tributyltin in mice. Environ Health Perspect 121(3):359–366, PMID: 23322813,
https://doi.org/10.1289/ehp.1205701.
Chanda S, Dasgupta UB, Guhamazumder D, Gupta M, Chaudhuri U, Lahiri S, et al.
2006. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-
exposed people with and without malignancy. Toxicol Sci 89(2):431–437, PMID:
16251483, https://doi.org/10.1093/toxsci/kfj030.
Chervona Y, Hall MN, Arita A, Wu F, Sun H, Tseng HC, et al. 2012. Associations
between arsenic exposure and global posttranslational histone modifica-
tions among adults in Bangladesh. Cancer Epidemiol Biomarkers Prev
21(12):2252–2260, PMID: 23064002, https://doi.org/10.1158/1055-9965.EPI-12-
0833.
Cheung WA, Shao X, Morin A, Siroux V, Kwan T, Ge B, et al. 2017. Functional varia-
tion in allelic methylomes underscores a strong genetic contribution and
reveals novel epigenetic alterations in the human epigenome. Genome Biol
18(1):50, PMID: 28283040, https://doi.org/10.1186/s13059-017-1173-7.
Clapier CR, Cairns BR. 2009. The biology of chromatin remodeling complexes. Annu
Rev Biochem 78:273–304, PMID: 19355820, https://doi.org/10.1146/annurev.
biochem.77.062706.153223.
de Conti A, Tryndyak V, Doerge DR, Beland FA, Pogribny IP. 2016. Irreversible
down-regulation of miR-375 in the livers of Fischer 344 rats after chronic furan
exposure. Food Chem Toxicol 98(Part A):2–10, PMID: 27371368, https://doi.org/
10.1016/j.fct.2016.06.027.
Desai M, Beall M, Ross MG. 2013. Developmental origins of obesity: programmed
adipogenesis. Curr Diab Rep 13(1):27–33, PMID: 23188593, https://doi.org/10.
1007/s11892-012-0344-x.
Dhir A, Dhir S, Proudfoot NJ, Jopling CL. 2015. Microprocessor mediates transcrip-
tional termination of long noncoding RNA transcripts hosting microRNAs. Nat
Struct Mol Biol 22(4):319–327, PMID: 25730776, https://doi.org/10.1038/nsmb.
2982.
Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA. 2016. Adverse out-
come pathways-organizing toxicological information to improve decision mak-
ing. J Pharmacol Exp Ther 356(1):170–181, PMID: 26537250, https://doi.org/10.
1124/jpet.115.228239.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. 2007. MicroRNA-
29 family reverts aberrant methylation in lung cancer by targeting DNA methyl-
transferases 3A and 3B. Proc Natl Acad Sci U S A 104(40):15805–15810, PMID:
17890317, https://doi.org/10.1073/pnas.0707628104.
Ferreira DW, Allard P. 2015. Models of germ cell development and their application
for toxicity studies. Environ Mol Mutagen 56(8):637–649, PMID: 25821157,
https://doi.org/10.1002/em.21946.
Field SF, Beraldi D, Bachman M, Stewart SK, Beck S, Balasubramanian S. 2015.
Accurate measurement of 5-methylcytosine and 5-hydroxymethylcytosine in
human cerebellum DNA by oxidative bisulfite on an array (OxBS-array). PloS
One 10(2):e0118202, PMID: 25706862, https://doi.org/10.1371/journal.pone.0118202.
Filippakopoulos P, Knapp S. 2012. The bromodomain interaction module. FEBS Lett
586(17):2692–2704, PMID: 22710155, https://doi.org/10.1016/j.febslet.2012.04.045.
Grant PA, Duggan L, Côté J, Roberts SM, Brownell JE, Candau R, et al. 1997. Yeast
Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histo-
nes: characterization of an Ada complex and the SAGA (Spt/Ada) complex.
Genes Dev 11(13):1640–1650, PMID: 9224714, https://doi.org/10.1101/gad.11.13.
1640.
Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. 2007. A chromatin land-
mark and transcription initiation at most promoters in human cells. Cell
130(1):77–88, PMID: 17632057, https://doi.org/10.1016/j.cell.2007.05.042.
Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, et al. 2013.
Germline DNA demethylation dynamics and imprint erasure through 5-hydroxy-
methylcytosine. Science 339(6118):448–452, PMID: 23223451, https://doi.org/10.
1126/science.1229277.
Hackett JA, Surani MA. 2013. Beyond DNA: programming and inheritance of pa-
rental methylomes. Cell 153(4):737–739, PMID: 23663772, https://doi.org/10.1016/
j.cell.2013.04.044.
Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al.
2011. Increased methylation variation in epigenetic domains across cancer
types. Nat Genet 43(8):768–775, PMID: 21706001, https://doi.org/10.1038/ng.865.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al.
2013. Natural RNA circles function as efficient microRNA sponges. Nature
495(7441):384–388, PMID: 23446346, https://doi.org/10.1038/nature11993.
Harrill AH, McCullough SD, Wood CE, Kahle JJ, Chorley BN. 2016. MicroRNA bio-
markers of toxicity in biological matrices. Toxicol Sci 152(2):264–272, PMID:
27462126, https://doi.org/10.1093/toxsci/kfw090.
Harris KD, Bartlett NJ, Lloyd VK. 2012. Daphnia as an emerging epigenetic model
organism. Genet Res Int 2012:147892, PMID: 22567376, https://doi.org/10.1155/
2012/147892.
Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. 2007.
Distinct and predictive chromatin signatures of transcriptional promoters
and enhancers in the human genome. Nat Genet 39(3):311–318, PMID:
17277777, https://doi.org/10.1038/ng1966.
Hodjat M, Rahmani S, Khan F, Niaz K, Navaei-Nigjeh M, Mohammadi Nejad S, et al.
2017. Environmental toxicants, incidence of degenerative diseases, and thera-
pies from the epigenetic point of view. Arch Toxicol 91(7):2577–2597, PMID:
28516248, https://doi.org/10.1007/s00204-017-1979-9.
Hou LD, Zhang J. 2017. Circular RNAs: An emerging type of RNA in cancer. Int J
Immunopathol Pharmacol 30(1):1–6, PMID: 28134598, https://doi.org/10.1177/
0394632016686985.
Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. 2001. A
cellular function for the RNA-interference enzyme dicer in the maturation of
the let-7 small temporal RNA. Science 293(5531):834–838, PMID: 11452083,
https://doi.org/10.1126/science.1062961.
James KL, Randall NP, Haddaway NR. 2016. A methodology for systematic map-
ping in environmental sciences. Environ Evid 5:7, https://doi.org/10.1186/s13750-
016-0059-6.
Johnson RL, Huang W, Jadhav A, Austin CP, Inglese J, Martinez ED. 2008. A quanti-
tative high-throughput screen identifies potential epigenetic modulators of gene
expression. Anal Biochem 375(2):237–248, PMID: 18211814, https://doi.org/10.
1016/j.ab.2007.12.028.
Kafer GR, Li X, Horii T, Suetake I, Tajima S, Hatada I, et al. 2016. 5-
Hydroxymethylcytosine marks sites of DNA damage and promotes genome
stability. Cell Rep 14(6):1283–1292, PMID: 26854228, https://doi.org/10.1016/j.
celrep.2016.01.035.
Kan PY, Caterino TL, Hayes JJ. 2009. The H4 tail domain participates in intra- and
internucleosome interactions with protein and DNA during folding and oligo-
merization of nucleosome arrays. Mol Cell Biol 29(2):538–546, PMID: 19001093,
https://doi.org/10.1128/MCB.01343-08.
Kelly WG, Xu S, Montgomery MK, Fire A. 1997. Distinct requirements for somatic
and germline expression of a generally expressed Caernorhabditis elegans
gene. Genetics 146(1):227–238, PMID: 9136012.
Knapen D, Angrish M, Fortin M, Katsiadaki I, Lènoard M, Margiotta-Casaluci L,
et al. 2018. Adverse outcome pathway networks I: development and applica-
tions. Environ Toxicol Chem, PMID: 29488651, https://doi.org/10.1002/etc.4125.
Kong AP, Xiao K, Choi KC, Wang G, Chan MH, Ho CS, et al. 2012. Associations
between microRNA (miR-21, 126, 155 and 221), albuminuria and heavy metals
in Hong Kong Chinese adolescents. Clin Chim Acta 413(13–14):1053–1057,
PMID: 22405870, https://doi.org/10.1016/j.cca.2012.02.014.
Kouzarides T. 2007. Chromatin modifications and their function. Cell 128(4):693–705,
PMID: 17320507, https://doi.org/10.1016/j.cell.2007.02.005.
Lee KK, Workman JL. 2007. Histone acetyltransferase complexes: one size doesn't
fit all. Nat Rev Mol Cell Biol 8(4):284–295, PMID: 17380162, https://doi.org/10.
1038/nrm2145.
Environmental Health Perspectives 045001-10
Levine AJ, Oren M. 2009. The first 30 years of p53: growing ever more complex.
Nat Rev Cancer 9(10):749–758, PMID: 19776744, https://doi.org/10.1038/nrc2723.
Li G, Reinberg D. 2011. Chromatin higher-order structures and gene regulation.
Curr Opin Genet Dev 21(2):175–186, PMID: 21342762, https://doi.org/10.1016/j.
gde.2011.01.022.
Li W, Notani D, Rosenfeld MG. 2016. Enhancers as non-coding RNA transcription
units: recent insights and future perspectives. Nat Rev Genet 17(4):207–223,
PMID: 26948815, https://doi.org/10.1038/nrg.2016.4.
Ludwig AK, Zhang P, Cardoso MC. 2016. Modifiers and readers of DNA modifica-
tions and their impact on genome structure, expression, and stability in dis-
ease. Front Genet 7:115, PMID: 27446199, https://doi.org/10.3389/fgene.2016.
00115.
Lundby Z, Camacho J, Allard P. 2016. Fast functional germline and epigenetic
assays in the nematode Caenorhabditis elegans. Methods Mol Biol 1473:99–
107, PMID: 27518628, https://doi.org/10.1007/978-1-4939-6346-1_11.
Manikkam M, Guerrero-Bosagna C, Tracey R, Haque MM, Skinner MK. 2012.
Transgenerational actions of environmental compounds on reproductive dis-
ease and identification of epigenetic biomarkers of ancestral exposures. PLoS
One 7(2):e31901, PMID: 22389676, https://doi.org/10.1371/journal.pone.0031901.
Martin C, Zhang Y. 2005. The diverse functions of histone lysine methylation. Nat Rev
Mol Cell Biol 6(11):838–849, PMID: 16261189, https://doi.org/10.1038/nrm1761.
Martinez ED, Dull AB, Beutler JA, Hager GL. 2006. High-content fluorescence-
based screening for epigenetic modulators. Meth Enzymol 414:21–36, PMID:
17110184, https://doi.org/10.1016/S0076-6879(06)14002-1.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. 2013. Circular
RNAs are a large class of animal RNAs with regulatory potency. Nature
495(7441):333–338, PMID: 23446348, https://doi.org/10.1038/nature11928.
Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN. 2007.
Developmental exposure to endocrine disruptors and the obesity epidemic.
Reprod Toxicol 23(3):290–296, PMID: 17321108, https://doi.org/10.1016/j.reprotox.
2006.12.010.
NRC (National Research Council). 2009. “Science and Decisions: Advancing
Risk Assessment.” Washington, DC: National Academies Press. https://www.
nap.edu/catalog/12209/science-and-decisions-advancing-risk-assessment
[accessed 9 June 2017].
OECD (Organisation for Economic Co-operation and Development). 2013. “Guidance
Document on Developing and Assessing Adverse Outcome Pathways. (Series
on Testing and Assessment, No. 184).” Environment Directorate Paris, France:
Organisation for Economic Cooperation and Development. http://search.oecd.
org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2013)6&
doclanguage=en [accessed 9 June 2017].
OECD. 2016. “Guidance Document for the Use of Adverse Outcome Pathways in
Developing Integrated Approaches to Testing and Assessment (IATA) Series on
Testing & Assessment No. 260.” Paris, France:Environment Directorate OECD.
https://one.oecd.org/document/ENV/JM/MONO(2016)67/en/pdf [accessed 9 June
2017].
Parodi DA, Damoiseaux R, Allard P. 2015. Comprehensive assessment of germline
chemical toxicity using the nematode Caenorhabditis elegans. J Vis Exp (96):
e52445, PMID: 25741987, https://doi.org/10.3791/52445.
Rager JE, Moeller BC, Miller SK, Kracko D, Doyle-Eisele M, Swenberg JA, et al.
2014. Formaldehyde-associated changes in microRNAs: Tissue and temporal
specificity in the rat nose, white blood cells, and bone marrow. Toxicol Sci
138(1):36–46, PMID: 24304932, https://doi.org/10.1093/toxsci/kft267.
Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M,
Yen A, et al. 2015. Integrative analysis of 111 reference human epigenomes.
Nature 518(7539):317–330, PMID: 25693563, https://doi.org/10.1038/nature14248.
Robichaud NF, Sassine J, Beaton MJ, Lloyd VK. 2012. The epigenetic repertoire of
Daphnia magna includes modified histones. Genet Res Int 2012:174860, PMID:
22567378, https://doi.org/10.1155/2012/174860.
Rotem A, Ram O, Shoresh N, Sperling RA, Goren A, Weitz DA, et al. 2015. Single-
cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat
Biotechnol 33(11):1165–1172, PMID: 26458175, https://doi.org/10.1038/nbt.3383.
Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. 2006.
Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer
Cell 9(6):435–443, PMID: 16766263, https://doi.org/10.1016/j.ccr.2006.04.020.
Shinjo K, Kondo Y. 2015. Targeting cancer epigenetics: linking basic biology to clin-
ical medicine. Adv Drug Deliv Rev 95:56–64, PMID: 26494398, https://doi.org/10.
1016/j.addr.2015.10.006.
Skinner MK, Manikkam M, Tracey R, Guerrero-Bosagna C, Haque M, Nilsson EE.
2013. Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epi-
genetic transgenerational inheritance of obesity. BMC Med 11:228, PMID:
24228800, https://doi.org/10.1186/1741-7015-11-228.
Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. 2010. MicroRNAs,
macrocontrol: regulation of miRNA processing. RNA 16(6):1087–1095, PMID:
20423980, https://doi.org/10.1261/rna.1804410.
Smeester L, Rager JE, Bailey KA, Guan X, Smith N, García-Vargas G, et al. 2011.
Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol
24(2):165–167, PMID: 21291286, https://doi.org/10.1021/tx1004419.
Step SE, Lim HW, Marinis JM, Prokesch A, Steger DJ, You SH, et al. 2014. Anti-dia-
betic rosiglitazone remodels the adipocyte transcriptome by redistributing
transcription to PPARc-driven enhancers. Genes Dev 28(9):1018–1028, PMID:
24788520, https://doi.org/10.1101/gad.237628.114.
Sterne JA, Hernán MA, Reeves BC, Savovic´ J, Berkman ND, Viswanathan M, et al.
2016. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
interventions. BMJ 355:i4919, PMID: 27733354, https://doi.org/10.1136/bmj.i4919.
Stiegel MA, Pleil JD, Sobus JR, Madden MC. 2016. Inflammatory cytokines and
white blood cell counts response to environmental levels of diesel exhaust
and ozone inhalation exposures. PLoS One 11(4):e0152458, PMID: 27058360,
https://doi.org/10.1371/journal.pone.0152458.
Stollewerk A. 2010. The water flea Daphnia–a 'new' model system for ecology and
evolution? J Biol 9:21, PMID: 20478012, https://doi.org/10.1186/jbiol212.
Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature
403(6765):41–45, PMID: 10638745, https://doi.org/10.1038/47412.
Stunnenberg HG, International Human Epigenome Consortium, Hirst M. 2016. The
international human epigenome consortium: a blueprint for scientific collabo-
ration and discovery. Cell 167(5):1145–1149, PMID: 27863232, https://doi.org/10.
1016/j.cell.2016.11.007.
Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, et al.
2014. Applying adverse outcome pathways (AOPs) to support integrated
approaches to testing and assessment (IATA). Regul Toxicol Pharmacol
70(3):629–640, PMID: 25261300, https://doi.org/10.1016/j.yrtph.2014.09.009.
Tracey R, Manikkam M, Guerrero-Bosagna C, Skinner MK. 2013. Hydrocarbons (jet
fuel JP-8) induce epigenetic transgenerational inheritance of obesity, repro-
ductive disease and sperm epimutations. Reprod Toxicol 36:104–116, PMID:
23453003, https://doi.org/10.1016/j.reprotox.2012.11.011.
Tsang V, Fry RC, Niculescu MD, Rager JE, Saunders J, Paul DS, et al. 2012. The
epigenetic effects of a high prenatal folate intake in male mouse fetuses
exposed in utero to arsenic. Toxicol Appl Pharmacol 264(3):439–450, PMID:
22959928, https://doi.org/10.1016/j.taap.2012.08.022.
Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. 1968. Prevalence of skin
cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer
Inst 40(3):453–463, PMID: 5644201.
Tseng WP. 1977. Effects and dose–response relationships of skin cancer and
blackfoot disease with arsenic. Environ Health Perspect 19:109–119, PMID:
908285, https://doi.org/10.1289/ehp.7719109.
Tsompana M, Buck MJ. 2014. Chromatin accessibility: a window into the genome.
Epigenetics Chromatin 7(1):33, PMID: 25473421, https://doi.org/10.1186/1756-
8935-7-33.
Tuddenham L, Wheeler G, Ntounia-Fousara S, Waters J, Hajihosseini MK, Clark I,
et al. 2006. The cartilage specific microRNA-140 targets histone deacetylase 4
in mouse cells. FEBS Lett 580(17):4214–4217, PMID: 16828749, https://doi.org/10.
1016/j.febslet.2006.06.080.
Tyler CR, Hafez AK, Solomon ER, Allan AM. 2015a. Developmental exposure to 50
parts-per-billion arsenic influences histone modifications and associated epi-
genetic machinery in a region- and sex-specific manner in the adult mouse
brain. Toxicol Appl Pharmacol 288(1):40–51, PMID: 26193056, https://doi.org/10.
1016/j.taap.2015.07.013.
Tyler CR, Weber JA, Labrecque M, Hessinger JM, Edwards JS, Allan AM. 2015b.
ChIP-seq analysis of the adult male mouse brain after developmental exposure
to arsenic. Data Brief 5:248–254, PMID: 26543888, https://doi.org/10.1016/j.dib.
2015.08.037.
Vahter M, Marafante E. 1988. In Vivo Methylation and Detoxification of Arsenic.
Oxford, UK:Royal Society of Chemistry.
Vandegehuchte MB, Kyndt T, Vanholme B, Haegeman A, Gheysen G, Janssen
CR. 2009. Occurrence of DNA methylation in Daphnia magna and influence
of multigeneration Cd exposure. Environ Int 35(4):700–706, PMID: 19249097,
https://doi.org/10.1016/j.envint.2009.01.002.
Vandegehuchte MB, Lemière F, Vanhaecke L, Vanden Berghe W, Janssen CR. 2010.
Direct and transgenerational impact on Daphnia magna of chemicals with a
known effect on DNA methylation. Comp Biochem Physiol C Toxicol Pharmacol
151(3):278–285, PMID: 19961956, https://doi.org/10.1016/j.cbpc.2009.11.007.
Venkatesh S, Workman JL. 2015. Histone exchange, chromatin structure and the
regulation of transcription. Nat Rev Mol Cell Biol 16(3):178–189, PMID: 25650798,
https://doi.org/10.1038/nrm3941.
Villeneuve D, Angrish M, Fortin M, Katsiadaki I, Lènoard M, Margiotta-Casaluci L,
et al. 2018. Adverse outcome pathway networks II: network analytics. Environ
Toxicol Chem, https://doi.org/10.1002/etc.4124.
Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA,
et al. 2014a. Adverse outcome pathway (AOP) development I: strategies and prin-
ciples. Toxicol Sci 142(2):312–320, PMID: 25466378, https://doi.org/10.1093/toxsci/
kfu199.
Environmental Health Perspectives 045001-11
Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone
CA, et al. 2014b. Adverse outcome pathway development II: best practices.
Toxicol Sci 142(2):321–330, PMID: 25466379, https://doi.org/10.1093/toxsci/
kfu200.
Vinken M, Knapen D, Vergauwen L, Hengstler JG, Angrish M, Whelan M. 2017.
Adverse outcome pathways: A concise introduction for toxicologists. Arch
Toxicol 91(11):3697–3707, PMID: 28660287, https://doi.org/10.1007/s00204-017-
2020-z.
Wang K, Zhang S, Weber J, Baxter D, Galas DJ. 2010. Export of microRNAs and
microRNA-protective protein by mammalian cells. Nucleic Acids Res
38(20):7248–7259, PMID: 20615901, https://doi.org/10.1093/nar/gkq601.
Wang Z, Humphries B, Xiao H, Jiang Y, Yang C. 2014. MicroRNA-200b suppresses
arsenic-transformed cell migration by targeting protein kinase Cα and Wnt5b-
protein kinase Cα positive feedback loop and inhibiting Rac1 activation. J Biol
Chem 289(26):18373–18386, PMID: 24841200, https://doi.org/10.1074/jbc.M114.
554246.
Wang Z, Zhao Y, Smith E, Goodall GJ, Drew PA, Brabletz T, et al. 2011. Reversal
and prevention of arsenic-induced human bronchial epithelial cell malignant
transformation by microRNA-200b. Toxicol Sci 121(1):110–122, PMID: 21292642,
https://doi.org/10.1093/toxsci/kfr029.
Wilusz JE, JnBaptiste CK, Lu LY, Kuhn CD, Joshua-Tor L, Sharp PA. 2012. A triple
helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails.
Genes Dev 26(21):2392–2407, PMID: 23073843, https://doi.org/10.1101/gad.
204438.112.
Yang XJ, Seto E. 2008. Lysine acetylation: codified crosstalk with other posttransla-
tional modifications. Mol Cell 31(4):449–461, PMID: 18722172, https://doi.org/10.
1016/j.molcel.2008.07.002.
Yokota J. 2000. Tumor progression and metastasis. Carcinogenesis 21(3):497–503,
PMID: 10688870, https://doi.org/10.1093/carcin/21.3.497.
Zierold KM, Knobeloch L, Anderson H. 2004. Prevalence of chronic diseases in
adults exposed to arsenic-contaminated drinking water. Am J Public Health
94(11):1936–1937, PMID: 15514231, https://doi.org/10.2105/AJPH.94.11.1936.
Environmental Health Perspectives 045001-12
